TCGA-BH-A42U-01A-12R-A24H-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 112
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.460
- MYOGENESIS+0.450
- COAGULATION+0.350
- KRAS_SIGNALING_DN+0.330
- P53_PATHWAY+0.320
- ALLOGRAFT_REJECTION+0.290
- APICAL_JUNCTION+0.290
- KRAS_SIGNALING_UP+0.280
- INFLAMMATORY_RESPONSE+0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.260
Top 10 suppressed
- E2F_TARGETS-0.610
- G2M_CHECKPOINT-0.610
- PROTEIN_SECRETION-0.590
- MITOTIC_SPINDLE-0.490
- MTORC1_SIGNALING-0.470
- MYC_TARGETS_V1-0.420
- UNFOLDED_PROTEIN_RESPONSE-0.370
- PI3K_AKT_MTOR_SIGNALING-0.310
- ANDROGEN_RESPONSE-0.290
- GLYCOLYSIS-0.270
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-Z7-A8R5-01A-42R-A41B-07 | — | B | 0.926 |
| 2 | TCGA-GM-A3XN-01A-12R-A22U-07 | — | A | 0.910 |
| 3 | TCGA-AR-A2LJ-01A-12R-A19W-07 | — | B | 0.906 |
| 4 | TCGA-FD-A43S-01A-21R-A23W-07 | — | — | 0.902 |
| 5 | TCGA-A2-A3XW-01A-11R-A239-07 | — | B | 0.895 |
| 6 | TCGA-GM-A4E0-01A-12R-A266-07 | — | A | 0.890 |
| 7 | TCGA-AC-A3BB-01A-21R-A19W-07 | — | A | 0.886 |
| 8 | TCGA-A2-A0CR-01A-11R-A22K-07 | — | B | 0.885 |
| 9 | BS_NPQJ20KX | pilocytic astrocytoma | — | 0.883 |
| 10 | R281 | — | — | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.460 | Inavolisib | — uncovered |
| MYOGENESIS | 0.450 | Inavolisib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.330 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.320 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.290 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.270 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.260 | Inavolisib | — uncovered |
| HYPOXIA | 0.240 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.230 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.130 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.110 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |